Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy

dc.authoridKAYTAZ TEKYOL, Kubra/0000-0002-1898-3119
dc.contributor.authorGurleyik, Gunay
dc.contributor.authorAksu, Sibel Aydin
dc.contributor.authorAker, Fugen
dc.contributor.authorTekyol, Kubra Kaytaz
dc.contributor.authorTanrikulu, Eda
dc.contributor.authorGurleyik, Emin
dc.date.accessioned2021-12-01T18:48:59Z
dc.date.available2021-12-01T18:48:59Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractPurpose: Accurate restaging of the axilla after neoadjuvant chemotherapy (NAC) is an important issue to ensure deescalating axillary surgery in patients with initial metastatic nodes. We aimed to present our results of targeted axillary biopsy (TAB) combined with sentinel lymph node biopsy (SLNB) for axillary restaging after NAC. Methods: In 64 breast cancer patients who underwent NAC, biopsy-proven positive nodes were marked with clips before NAC, and ultrasound-guided wire localization of clip-marked nodes was performed after NAC. Patients underwent TAB and SLNB for post-NAC axilla restaging. Results: Identification rates of post-NAC TAB and SLNB were 98.4% and 87.5%, respectively (P = 0.033). Histopathology revealed a nodal pathologic complete response (pCR) rate of 47% in which axillary lymph node dissection (ALND) was avoided. TAB alone and SLNB alone detected residual disease in 29 (85.3%) and 20 (58.8%) patients (P = 0.029), respectively. Whereas rates of up to 97% had been achieved with a combination of TAB and SLNB. The pCR rates after NAC were 64.3% for human epidermal growth factor receptor 2 positive and triple-negative tumors and 13.6% in luminal tumors (P = 0.0002). Conclusion: Pathologic analysis following TAB combined with SLNB revealed the pCR rates to NAC in a considerable number of patients that provided de-escalation of axillary surgery. A combination of SLNB and TAB was found to be an accurate procedure in establishing residual nodal disease. This combined procedure in patients with initially positive nodes was a reliable method for post-NAC axillary restaging.en_US
dc.identifier.doi10.4174/astr.2021.100.6.305
dc.identifier.endpage312en_US
dc.identifier.issn2288-6575
dc.identifier.issn2288-6796
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85107531288en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage305en_US
dc.identifier.urihttps://doi.org/10.4174/astr.2021.100.6.305
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10644
dc.identifier.volume100en_US
dc.identifier.wosWOS:000658410700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKorean Surgical Societyen_US
dc.relation.ispartofAnnals Of Surgical Treatment And Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreasten_US
dc.subjectLymph nodesen_US
dc.subjectNeoplasmsen_US
dc.subjectPathologic responseen_US
dc.subjectSurgeryen_US
dc.subjectBreast-Cancer Patientsen_US
dc.subjectWire Localizationen_US
dc.subjectAccurateen_US
dc.subjectClipen_US
dc.titleTargeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10644.pdf
Boyut:
608.12 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text